1263284-59-8

Basic information

• Product Name: (R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate
• Synonyms: (R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate;(3R)-3-(4-Aminophenyl)-1-Piperidinecarboxylic acid tert-butyl ester;tert-butyl(R)-3-(4-aminophenyl)piperidine-1-carboxylate;EOS-60868
• CAS NO: 1263284-59-8
• Molecular Formula: C₁₆H₂₄N₂O₂
• Molecular Weight: 276
• Mol File: 1263284-59-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 412.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.100
• PKA: 4.96±0.10(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate(1263284-59-8)
• EPA Substance Registry System: (R)-tert-butyl 3-(4-aMinophenyl)piperidine-1-carboxylate(1263284-59-8)

Safety Data

• Hazardous Substances Data: 1263284-59-8(Hazardous Substances Data)

Usage

Description

(R)-tert-Butyl 3-(4-aminophenyl)piperidine-1-carboxylate is an organic compound that serves as a crucial intermediate in the synthesis of Niraparib (N481400), a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor. (R)-tert-Butyl 3-(4-aminophenyl)piperidine-1-carboxylate plays a significant role in the development of pharmaceuticals targeting BRCA-1 and -2 mutant tumors.

Uses

Used in Pharmaceutical Industry:
(R)-tert-Butyl 3-(4-aminophenyl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of Niraparib, a novel oral PARP inhibitor. It is particularly effective against BRCA-1 and -2 mutant tumors, making it a valuable compound in the development of targeted cancer therapies.
As an intermediate in the production of Niraparib, (R)-tert-Butyl 3-(4-aminophenyl)piperidine-1-carboxylate contributes to the development of a potent and selective PARP inhibitor. This inhibitor has demonstrated efficacy in treating tumors with BRCA-1 and -2 mutations, which are often associated with a higher risk of developing certain types of cancer, such as ovarian and breast cancer. The compound's role in the synthesis of Niraparib highlights its importance in the pharmaceutical industry, where it aids in the creation of innovative and effective cancer treatments.

Upstream product

• 875798-79-1 3-(4-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 4282-46-6 3-(4'-nitrophenyl)pyridine 
• 19733-56-3 3-(4-aminophenyl)piperidine 
• 1692-25-7 3-pyridylboronic acid 
• 586-78-7 para-nitrophenyl bromide 

Relevant articles and documents

Development of a fit-for-purpose large-scale synthesis of an oral PARP inhibitor

Compound (1) a poly(ADP-ribose)polymerase (PARP) inhibitor has been made by a fit-for-purpose large-scale synthesis using either a classical resolution or chiral chromatographic separation. The development and relative merits of each route are discussed,

SUBSTITUTED BENZAMIDES

The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.